{"entity":{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","aka":[],"tldr":"Immunologist who helped define the PD-1 pathway's role in cancer and built one of the largest immunotherapy institutes.","summary":"Drew M. Pardoll is Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is a tumour immunologist who helped define the role of the PD-1 pathway in cancer, co-discovering PD-L2 and contributing to the clinical development of PD-1 blockade. His selected paper reviews the blockade of immune checkpoints in cancer immunotherapy. He now directs one of the largest immunotherapy institutes, with continued interests in immune checkpoint inhibitors and cancer vaccines.","asOf":"2026-09-08","links":[{"label":"Bloomberg~Kimmel Institute","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/bloomberg-kimmel-institute-cancer-immunotherapy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pardoll%20DM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":["johns-hopkins"],"pathways":["pd1-checkpoint"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"role":"Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy","institutionId":"johns-hopkins","specialisms":["Tumour immunology","PD-1 pathway","Cancer vaccines"],"profiles":[{"label":"Bloomberg~Kimmel Institute","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center/research/bloomberg-kimmel-institute-cancer-immunotherapy"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pardoll%20DM%5BAuthor%5D"}],"papers":[{"title":"The blockade of immune checkpoints in cancer immunotherapy","journal":"Nature Reviews Cancer","year":2012,"url":"https://doi.org/10.1038/nrc3239","doi":"10.1038/nrc3239"},{"title":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","journal":"PNAS","year":2002,"url":"https://doi.org/10.1073/pnas.192461099","doi":"10.1073/pnas.192461099"},{"title":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1500596","doi":"10.1056/NEJMoa1500596"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}],"orcid":"0000-0001-6215-1013"},"route":"/people/drew-pardoll/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"}],"pathway":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"}],"journal":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/"}],"person":[{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/"}],"paper":[{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/"},{"id":"paper-pardoll-immune-checkpoint-blockade-nrc-2012","kind":"paper","name":"Pardoll 2012: the blockade of immune checkpoints in cancer immunotherapy","route":"/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/"}],"term":[{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/"}]}}